Lung Cancer News

The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer.

BOSTON — Completing a CT scan and ordering lung cancer screening occurred more frequently if eligible patients received a digital health program intervention vs. enhanced usual care, according to data presented at the CHEST Annual Meeting.

The FDA expanded the approval of nivolumab for treatment of non-small cell lung cancer.

The FDA has granted 510(k) clearance to qCT LN Quant, an AI solution that aids clinicians in finding lung nodule diameters, malignancy risk and management approaches, according to a manufacturer-issued press release.

A randomized phase 2 trial of individuals with cancer cachexia showed those assigned ponsegromab gained significantly more weight than those assigned placebo.

The FDA approved osimertinib for treatment of certain patients with locally advanced or unresectable non-small cell lung cancer.

The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent’s manufacturer.

The introduction of immunotherapy to treatment paradigms has improved survival for patients with metastatic non-small cell lung cancer, according to study results.

Patritumab deruxtecan improved PFS compared with chemotherapy among certain patients with advanced non-small cell lung cancer, according to the agent’s manufacturer.

The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection.